Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas

Zentralblatt fur Neurochirurgie

Volumn 67, Issue 4, 2006, Pages 204-209

  Maiuri, Francesco ^a,b   Del Basso De Caro, M L ^a   Iaconetta, G ^a   Peca, C ^a   Esposito, M ^a   De Divitiis, E ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Brain tumor; Growth factor; Oligodendroglioma; Survival; Tumor marker

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR; TEMOZOLOMIDE; TENASCIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGING; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL PROLIFERATION; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; OLIGODENDROGLIOMA; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33845606274     PISSN: 00444251     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942138     Document Type: Review

References (42)

1. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998; 88: 513-520
2. Berger MS, Deliganis AV, Dobbins J et al. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer 1994; 74: 1784-1791
3. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold Jr SC, Bullard DE. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987; 59: 1345-1352
4. th edn. Churchill-Livingstone, New York 2002; 234-235
5. Caincross JG, Meki K, Zlatescu MC. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Nat Cancer Inst 1998; 90: 1473-1479
6. Celli P, Nofrone I, Palma L, Cantore GP, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-1034
7. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997; 41: 878-885
8. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol 1997; 34: 61-78
9. Dehghani F, Schachenmayr W, Laun A, Korf HW. Prognostic implications of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 1998; 95: 493-504
10. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998; 42: 341-346
11. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002; 58: 111-117
12. Engelhard HH, Stelea AC. Oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol 2003; 60: 443-455
13. Ganju V, Jenkins RB, O'Fallon JR. Prognostic factors in gliomas: a multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 1994; 74: 920-927
14. Giannini C, Scheithauer BW, Weaver MS, Burger PC, Kros JM, Mork S, Groeber MB, Bausermann S, Buckman JC, Buton J, Riepe R, Tazelaar HD, Nascimento AG, Gotty T, Keeney GL, Pernicone P, Altermatt I. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001; 60: 248-262
15. Heegard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995; 76: 1809-1813
16. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 2002; 58: 237-253
17. Korshunov A, Golanov A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J Neurooncol 2000; 48: 13-19
18. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107-1113
19. Kros JM, Pieterman H, Van Eden CG et al. Oligodendroglioma: the Rotterdam-Dijkaigt experience. Neurosurgery 1994; 34: 959-966
20. Kros JM, Zheng P, Wolbers GJ, Van der Bent MJ. Oligodendroglial tumors. In: Berger MS, Prados MD (eds). Textbook of Neuro-Oncology. Elsevier Saunders, Philadelphia 2005; chap 23: 163-176
21. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-372
22. Lindergaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoli R, Solgaard T, Dahl O, Ganz J. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987; 67: 224-230
23. Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoli R, Harvei S, Ganz J. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985; 63: 881-889
24. Mork SJ, Halvorsen TB, Lindegaard KF, Elde E. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986; 45: 65-78
25. Muemmer W, Hartmann C, Hoffmann A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-319
26. Pietsch T, Valter MM, Wolf HK, Deimling A von, Huang HJ, Cavenee WK, Wiestler OD. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997; 93: 109-117
27. Prayson RA, Mohan DS, Song P, Suh JH. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol 2000; 4: 218-227
28. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederhacher D, Wechsler W, Reifenberger G. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996; 55: 822-831
29. Reis-Filho JS, Faoro LN, Carrilho C, Bleggi-Torres LF, Schmitt FC. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma. Cancer 2000; 88: 862-869
30. Robinson S, Cohen M, Prayson R, Ransohoff R, Tabrizi N, Miller RH. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery 2001; 48: 864-870
31. th edn. Edward Arnold, London 1977; 195-203
32. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villano R, Bellotti C. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997; 24: 313-319
33. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76: 428-434
34. Smith JS, Wang XY, Qian J, Haschk SM, Scheithauer BW, Jenkins R, James CD. Amplification of platelet derived growth factor receptor (PDG FRA)-gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000; 59: 495-503
35. Stupp R, Dietrich PY, Ostermann-Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382
36. Sun EM, Genka S, Shitare N et al. Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 1988; 22: 886-891
37. Van der Bent MJ, Looijenga LH, Longberger K. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97: 1276-1284
38. Vaquero J, Zurita M, Coca S, Oya S, Morales C. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. Surg Neurol 2000; 54: 229-234
39. Warthon SB, Hamilton FA, Chan WK, Chan KK, Anderson JR. Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 1998; 24: 21-28
40. Westergaard L, Gjerris F, Klinken L. Prognostic factors in oligodendroglioma. Acta Neurochir 1997; 139: 600-605
41. Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 2002; 54: 1405-1409
42. rd edn. Springer, Berlin, Heidelberg 1986; 241